[静冈癌症中心质子治疗的初步临床经验]
[Initial clinical experience of proton therapy at Shizuoka Cancer Center].
作者信息
Murayama Shigeyuki, Fuji Hiroshi, Yamashita Haruo, Futami Yasuyuki, Numano Masumi, Harada Hideyuki, Kamata Minoru, Nishimura Tetsuo
机构信息
Proton Therapy Division, Shizuoka Cancer Center Hospital.
出版信息
Nihon Igaku Hoshasen Gakkai Zasshi. 2005 Oct;65(4):424-31.
PURPOSE
To present the initial experience and preliminary clinical results of patients treated mainly with proton irradiation at the newly developed proton therapy facility at Shizuoka Cancer Center.
MATERIALS AND METHODS
We reviewed 125 patients who underwent proton therapy between July 2003 and December 2004. Of these 125 patients, 11 had head and neck malignancies, 15 non-small cell lung cancers, 22 hepatocellular carcinomas, 62 prostate cancers, and 15 other malignant tumors.
RESULTS
Most patients experienced Grade 0-1 acute morbidities (NCI-CTC) in skin or mucosa, while a temporary Grade 2-3 reaction was observed in a high dose area. Response rates were 73% for H & N malignancies, 100% for NSCLC, and 77% for HCC. PSA evaluation for patients with prostate cancer revealed a high rate of complete response.
CONCLUSION
The efficacy and safety of proton therapy at Shizuoka Cancer Center was demonstrated for patients with early-stage cancer or locally advanced disease.
目的
介绍静冈癌症中心新开发的质子治疗设施中主要接受质子照射治疗的患者的初步经验和初步临床结果。
材料与方法
我们回顾了2003年7月至2004年12月期间接受质子治疗的125例患者。在这125例患者中，11例患有头颈部恶性肿瘤，15例为非小细胞肺癌，22例为肝细胞癌，62例为前列腺癌，15例为其他恶性肿瘤。
结果
大多数患者在皮肤或黏膜处出现0-1级急性不良反应（美国国立癌症研究所常见毒性标准），而在高剂量区域观察到暂时的2-3级反应。头颈部恶性肿瘤的缓解率为73%，非小细胞肺癌为100%，肝细胞癌为77%。对前列腺癌患者的前列腺特异性抗原评估显示完全缓解率很高。
结论
静冈癌症中心质子治疗对早期癌症或局部晚期疾病患者的有效性和安全性得到了证实。
Zotero 插件